Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 76

1.

A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumors.

Friday B, Lassere Y, Meyers CA, Mita A, Abbruzzese JL, Thomas MB.

Anticancer Res. 2012 May;32(5):1689-96.

PMID:
22593447
[PubMed - indexed for MEDLINE]
2.

Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.

Hammond-Thelin LA, Thomas MB, Iwasaki M, Abbruzzese JL, Lassere Y, Meyers CA, Hoff P, de Bono J, Norris J, Matsushita H, Mita A, Rowinsky EK.

Invest New Drugs. 2012 Feb;30(1):316-26. doi: 10.1007/s10637-010-9535-y. Epub 2010 Sep 14.

PMID:
20839029
[PubMed - indexed for MEDLINE]
3.

Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.

Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, Kuwata K, Hoff PM.

Cancer. 2006 Sep 15;107(6):1383-90.

PMID:
16902987
[PubMed - indexed for MEDLINE]
Free Article
4.

Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors.

Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff PM, Xiong H, Abbruzzese JL.

Invest New Drugs. 2008 Oct;26(5):445-54. doi: 10.1007/s10637-008-9142-3. Epub 2008 Jun 5.

PMID:
18528634
[PubMed - indexed for MEDLINE]
5.

Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.

Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.

Clin Cancer Res. 2003 Sep 15;9(11):4092-100.

PMID:
14519631
[PubMed - indexed for MEDLINE]
Free Article
6.

Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.

Sewak S, Sorich J, O'Leary J.

Anticancer Drugs. 2006 Jun;17(5):571-9.

PMID:
16702815
[PubMed - indexed for MEDLINE]
7.

Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.

Tamura K, Nakagawa K, Kurata T, Satoh T, Nogami T, Takeda K, Mitsuoka S, Yoshimura N, Kudoh S, Negoro S, Fukuoka M.

Cancer Chemother Pharmacol. 2007 Jul;60(2):285-93. Epub 2006 Nov 30.

PMID:
17136542
[PubMed - indexed for MEDLINE]
8.

Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.

Supko JG, Eder JP Jr, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, Clark JW.

Clin Cancer Res. 2003 Nov 1;9(14):5178-86.

PMID:
14613997
[PubMed - indexed for MEDLINE]
Free Article
9.

Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.

Herben VM, van Gijn R, Schellens JH, Schot M, Lieverst J, Hillebrand MJ, Schoemaker NE, Porro MG, Beijnen JH, ten Bokkel Huinink WW.

J Clin Oncol. 1999 Jun;17(6):1906-14.

PMID:
10561232
[PubMed - indexed for MEDLINE]
Free Article
10.

A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.

Kakolyris S, Kouroussis C, Souglakos J, Mavroudis D, Agelaki S, Kalbakis K, Androulakis N, Vardakis N, Vamvakas L, Georgoulias V.

Oncology. 2001;61(4):265-70.

PMID:
11721172
[PubMed - indexed for MEDLINE]
11.

A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.

Faivre S, Raymond E, Boige V, Gatineau M, Buthaut X, Rixe O, Bernareggi A, Camboni G, Armand JP.

Clin Cancer Res. 2001 Jan;7(1):43-50.

PMID:
11205916
[PubMed - indexed for MEDLINE]
Free Article
12.

Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors.

Ramnath N, Schwartz GN, Smith P, Bong D, Kanter P, Berdzik J, Creaven PJ.

Cancer Chemother Pharmacol. 2003 Mar;51(3):227-30. Epub 2003 Feb 25.

PMID:
12655441
[PubMed - indexed for MEDLINE]
13.

A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.

Forouzesh B, Takimoto CH, Goetz A, Diab S, Hammond LA, Smetzer L, Schwartz G, Gazak R, Callaghan JT, Von Hoff DD, Rowinsky EK.

Clin Cancer Res. 2003 Nov 15;9(15):5540-9.

PMID:
14654534
[PubMed - indexed for MEDLINE]
Free Article
14.

A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.

Rademaker-Lakhai JM, Terret C, Howell SB, Baud CM, De Boer RF, Pluim D, Beijnen JH, Schellens JH, Droz JP.

Clin Cancer Res. 2004 May 15;10(10):3386-95.

PMID:
15161693
[PubMed - indexed for MEDLINE]
Free Article
15.

Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.

Advani RH, Hurwitz HI, Gordon MS, Ebbinghaus SW, Mendelson DS, Wakelee HA, Hoch U, Silverman JA, Havrilla NA, Berman CJ, Fox JA, Allen RS, Adelman DC.

Clin Cancer Res. 2010 Apr 1;16(7):2167-75. doi: 10.1158/1078-0432.CCR-09-2236. Epub 2010 Mar 16.

PMID:
20233886
[PubMed - indexed for MEDLINE]
Free Article
16.

Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.

Yamada Y, Tamura T, Yamamoto N, Shimoyama T, Ueda Y, Murakami H, Kusaba H, Kamiya Y, Saka H, Tanigawara Y, McGovren JP, Natsumeda Y.

Cancer Chemother Pharmacol. 2006 Aug;58(2):173-82. Epub 2005 Nov 25.

PMID:
16308697
[PubMed - indexed for MEDLINE]
17.

Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer.

Schöffski P, Thate B, Beutel G, Bolte O, Otto D, Hofmann M, Ganser A, Jenner A, Cheverton P, Wanders J, Oguma T, Atsumi R, Satomi M.

Ann Oncol. 2004 Apr;15(4):671-9.

PMID:
15033678
[PubMed - indexed for MEDLINE]
Free Article
18.

Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.

Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Fields S, Von Hoff DD, Verweij J.

Clin Cancer Res. 1998 May;4(5):1153-8.

PMID:
9607572
[PubMed - indexed for MEDLINE]
Free Article
19.

A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.

Delaunoit T, Burch PA, Reid JM, Camoriano JK, Kobayash T, Braich TA, Kaur JS, Rubin J, Erlichman C.

Invest New Drugs. 2006 Jul;24(4):327-33.

PMID:
16502355
[PubMed - indexed for MEDLINE]
20.

Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors.

Massard C, Salazar R, Armand JP, Majem M, Deutsch E, García M, Oaknin A, Fernández-García EM, Soto A, Soria JC.

Invest New Drugs. 2012 Dec;30(6):2318-26. doi: 10.1007/s10637-011-9772-8. Epub 2012 Jan 4.

PMID:
22215532
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk